ReviewKidney international2008
Sphingosine-1-phosphate receptors: biology and therapeutic potential in kidney disease.
Review in Kidney international, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 70 citations in OpenAlex.
- Review
- Sphingolipid signaling in kidney diseases.American journal of physiology. Renal physiology · 2025Review
- Modulatory effects of black jujube melanoidins on gut microbiota and metabolic pathways in high-fat diet-induced obesity.Frontiers in nutrition · 2025Article
- Sphingosine 1-phosphate protective effect on human proximal tubule cells submitted to an in vitro ischemia model: the role of JAK2/STAT3.Journal of physiology and biochemistry · 2024Article
- Role of G protein coupled receptors in acute kidney injury.Cell communication and signaling : CCS · 2024Review
- Metabolic profiling reveals new serum signatures to discriminate lupus nephritis from systemic lupus erythematosus.Frontiers in immunology · 2022Article
- The enpp4 ectonucleotidase regulates kidney patterning signalling networks in Xenopus embryos.Communications biology · 2021Article
- Emerging roles for lymphatics in acute kidney injury: Beneficial or maleficent?Experimental biology and medicine (Maywood, N.J.) · 2021Article
- Coronavirus disease 2019 (COVID-19), human erythrocytes and the PKC-alpha/-beta inhibitor chelerythrine -possible therapeutic implication.Cell cycle (Georgetown, Tex.) · 2020Review
- Detrimental role of sphingosine kinase 1 in kidney damage in DOCA-salt hypertensive model: evidence from knockout mice.BMC nephrology · 2020Article
- FTY720 Regulates Mitochondria Biogenesis in Dendritic Cells to Prevent Kidney Ischemic Reperfusion Injury.Frontiers in immunology · 2020Article
- Sphingosine-1-phosphate signaling in blood pressure regulation.American journal of physiology. Renal physiology · 2019Review
- Knockout of Sphingosine Kinase 1 Attenuates Renal Fibrosis in Unilateral Ureteral Obstruction Model.American journal of nephrology · 2019Article
- Survival benefit of sphingosin-1-phosphate and receptors expressions in breast cancer patients.Cancer medicine · 2018Article
- Sphingolipids and Redox Signaling in Renal Regulation and Chronic Kidney Diseases.Antioxidants & redox signaling · 2018Article
- Sphingosine-1-phosphate (S1P) enhances glomerular endothelial cells activation mediated by anti-myeloperoxidase antibody-positive IgG.Journal of cellular and molecular medicine · 2018Article
- Sphingosine Kinase 2 Deficiency Attenuates Kidney FibrosisJournal of the American Society of Nephrology : JASN · 2017Article
- Innate Immune Response in Kidney Ischemia/Reperfusion Injury: Potential Target for Therapy.Journal of immunology research · 2017Review
- High-throughput chinmedomics-based prediction of effective components and targets from herbal medicine AS1350.Scientific reports · 2016Article
- Drug discovery in focal and segmental glomerulosclerosis.Kidney international · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
Abstract
The major sphingolipid metabolite, sphingosine-1-phosphate (S1P), has important biological functions. S1P is the ligand for a family of five G-protein-coupled receptors with distinct signaling pathways that regulate angiogenesis, vascular maturation, immunity, chemotaxis, and other important biological pathways. Recently, clinical trials have targeted S1P receptors (S1PRs) for autoimmune diseases and transplantation and have generated considerable interest in developing additional, more selective compounds. This review summarizes current knowledge on the biology of S1P and S1PRs that forms the basis for future drug development and the treatment of kidney disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.